Screening of novel indole steroids as cytochrome P450 substrates in silico

  • Ян U. Panada Institute for Physical Chemical Problems, Belarusian State University, 14 Lieninhradskaja Street, Minsk 220006, Belarus
  • Yaroslav V. Faletrov Institute for Physical Chemical Problems, Belarusian State University, 14 Lieninhradskaja Street, Minsk 220006, Belarus
  • Nina S. Frolova Institute for Physical Chemical Problems, Belarusian State University, 14 Lieninhradskaja Street, Minsk 220006, Belarus
  • Vladimir M. Shkumatov Institute for Physical Chemical Problems, Belarusian State University, 14 Lieninhradskaja Street, Minsk 220006, Belarus

Abstract

In this work we describe the modeling of interactions between indole steroids and steroidogenic cytochromes P450. The highest possible affinity is expected of enzymes involved in cholesterol transformation (i. e. CYP3A4, CYP7A1, CYP11A1). In case of pregnane and estrane-converting proteins a decrease in the binding energy of synthetic steroids is found. The variations in affinity are explained in terms of structural difference. These calculations imply that indole steroids are most likely to be hydroxylated at positions 4 and 7 as well as interfere with CYP17A1 activity by heme coordination.

Author Biographies

Ян U. Panada, Institute for Physical Chemical Problems, Belarusian State University, 14 Lieninhradskaja Street, Minsk 220006, Belarus

junior researcher at the laboratory of biochemistry of drugs

Yaroslav V. Faletrov, Institute for Physical Chemical Problems, Belarusian State University, 14 Lieninhradskaja Street, Minsk 220006, Belarus

PhD (chemistry); leading researcher at the laboratory of biochemistry of drugs

Nina S. Frolova, Institute for Physical Chemical Problems, Belarusian State University, 14 Lieninhradskaja Street, Minsk 220006, Belarus

researcher at the laboratory of biochemistry of drugs

Vladimir M. Shkumatov, Institute for Physical Chemical Problems, Belarusian State University, 14 Lieninhradskaja Street, Minsk 220006, Belarus

corresponding member of the Natio nal Academy of Sciences of Belarus, doctor of science (biology), full professor; head of the laboratory of biochemistry of drugs

References

  1. Cabeza M., Sánchez-Márquez A., Garrido M., et al. Recent advances in drug design and drug discovery for androgen-dependent diseases. Curr. Med. Chem. 2016. Vol. 23, No. 8. P. 792–815. DOI: 10.2174/0929867323666160210125642.
  2. Chen Z., Tao Z.-Z., Chen S.-M., et al. Indole-3-carbinol inhibits nasopharyngeal carcinoma growth through cell cycle arrest in vivo and in vitro. PLoS ONE. 2013. Vol. 8, issue 12. e82288. DOI: 10.1371/journal.pone.0082288.
  3. Sorriento D., del Giudice C., Bertamino A., et al. New small molecules, ISA27 and SM13, inhibit tumour growth inducing mitochondrial effects of p53. Br. J. Cancer. 2015. Vol. 112, No. 1. P. 77–85. DOI: 10.1038/bjc.2014.577.
  4. Ingallinella P., Bianchi E., Ladwa N. A., et al. Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency. Proc. Natl. Acad. Sci. U. S. A. 2009. Vol. 106, No. 14. P. 5801–5806. DOI: 10.1073/pnas.0901007106.
  5. Novikova L. A., Faletrov Ya. V., Kovaleva I. E., et al. From structure and functions of steroidogenic enzymes to new technologies of gene engineering. Biochemistry (Moscow). 2009. Vol. 74, No. 13. P. 1482–1504. DOI: 10.1134/S0006297909130057.
  6. Stresser D. M., Bjeldanes L. F., Bailey G. S., et al. The anticarcinogen 3,3′-diindolylmethane is an inhibitor of cytochrome P-450. J. Biochem. Toxicol. 1995. Vol. 10, No. 4. P. 191–201. DOI: 10.1002/jbt.2570100403.
  7. Parkin D. R., Malejka-Giganti D. Differences in the hepatic P450-dependent metabolism of estrogen and tamoxifen in response to treatment of rats with 3,3′-diindolylmethane and its parent compound indole-3-carbinol. Cancer Detect. Prev. 2004. Vol. 28, No. 1. P. 72–79. DOI: 10.1016/j.cdp.2003.11.006.
  8. Parkin D. R., Lu Y., Bliss R. L., et al. Inhibitory effects of a dietary phytochemical 3,3′-diindolylmethane on the phenobarbital-induced hepatic CYP mRNA expression and CYP-catalyzed reactions in female rats. Food Chem. Toxicol. 2008. Vol. 46, issue 7. P. 2451–2458. DOI: 10.1016/j.fct.2008.03.029.
  9. Dolušić E., Larrieu P., Moineaux L., et al. Tryptophan 2,3-dioxygenase (TDO) inhibitors. 3-(2-(Pyridyl)ethenyl)indoles as potential anticancer immunomodulators. J. Med. Chem. 2011. Vol. 54, No. 15. P. 5320 –5334. DOI: 10.1021/jm2006782.
  10. Moss G. P. (ed.). Nomenclature of steroids (recommendations 1989). Pure Appl. Chem. 1989. Vol. 61, issue 10. P. 1783–1822. DOI: 10.1351/pac198961101783.
  11. Trott O., Olson A. J. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading. J. Comput. Chem. 2010. Vol. 31, issue 2. P. 455– 461. DOI: 10.1002/jcc.21334.
  12. Kellis Jr. J. T., Sheets J. J., Vickery L. E. Amino-steroids as inhibitors and probes of the active site of cytochrome P-450scc. effects on the enzyme from different sources. J. Steroid Biochem. 1984. Vol. 20, issue 2. P. 671–676. DOI: 10.1016/0022-4731(84)90141-9.
  13. Diczfalusy U., Nylén H., Elander P., et al. 4β-Hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans. Br. J. Clin. Pharmacol. 2011. Vol. 71, issue 2. P. 183–189. DOI: 10.1111/j.1365-2125.2010.03773.x.
  14. Lewisa D. F. V., Lee-Robichaudb P. Molecular modelling of steroidogenic cytochromes P450 from families CYP11, CYP17, CYP19 and CYP21 based on the CYP102 crystal structure. J. Steroid Biochem. Mol. Biol. 1998. Vol. 66, issue 4. P. 217–233. DOI: 10.1016/S0960-0760(98)00032-6.
Published
2018-04-30
Keywords: indole steroids, cytochrome P450, molecular docking
How to Cite
PanadaЯ. U., Faletrov, Y. V., Frolova, N. S., & Shkumatov, V. M. (2018). Screening of novel indole steroids as cytochrome P450 substrates in silico. Journal of the Belarusian State University. Chemistry, 1, 28-34. Retrieved from https://journals.bsu.by/index.php/chemistry/article/view/1218
Issue
No 1 (2018): Journal of the Belarusian State University. Chemistry
Section
Original Articles

The authors who are published in this journal agree to the following:

  1. The authors retain copyright on the work and provide the journal with the right of first publication of the work on condition of license Creative Commons Attribution-NonCommercial. 4.0 International (CC BY-NC 4.0).
  2. The authors retain the right to enter into certain contractual agreements relating to the non-exclusive distribution of the published version of the work (e.g. post it on the institutional repository, publication in the book), with the reference to its original publication in this journal.
  3. The authors have the right to post their work on the Internet (e.g. on the institutional store or personal website) prior to and during the review process, conducted by the journal, as this may lead to a productive discussion and a large number of references to this work. (See The Effect of Open Access.)